TMCnet News
Spero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract InfectionsCAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced it will host a key opinion leader (KOL) call on oral tebipenem HBr for the treatment of complicated urinary tract infections on Wednesday, September 30, 2020 at 11:30 a.m. Eastern Time. The call will feature a presentation by KOL Keith Kaye, MD, MPH, University of Michigan Medical School, who will discuss the current treatment landscape and unmet medical need in complicated urinary tract infections (cUTI). Dr. Kaye will be available to answer questions during the call. Spero's management team will also discuss the recently announced positive top-line data from Spero’s ADAPT-PO Phase 3 clinical trial of oral tebipenem HBr for the treatment of cUTI and acute pyelonephritis (AP). The ADAPT-PO trial met its primary endpoint of demonstrating that oral tebipenem HBr is statistically non-inferior to intravenous ertapenem, the most commonly used carbapenem for the treatment of cUTI and AP.
A webcast of the presentation may also be accessed through the Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Investors and Media” tab. A replay of the presentation will be archived on the website for 90 days following the conclusion of the event. About Dr. Keith Kaye: He has devoted his career to the prevention and effective management of healthcare-associated infections. In addition to serving in a variety of quality improvement and administrative roles in infection prevention, antimicrobial stewardship, and quality and patient safety, he has served on national and international clinical guidelines committees. In addition to his clinical work, Dr. Kaye’s research interests include the development of antimicrobial resistance, particularly among gram-negativeorganisms; prevention of healthcare associated infections; management of hospital-acquired infections in the elderly; and innovative approaches to antimicrobial stewardship. He has a long and consistent record of federal funding for research pertaining to management and prevention of multi-drug resistant organisms and healthcare-associated infections, including groundbreaking clinical trials. Dr. Kaye received his medical degree from the University of Pennsylvania and completed his Internal Medicine residency and Infectious Diseases fellowship at Beth Israel Deaconess Medical Center in Boston, MA. During fellowship, Dr. Kaye earned a Masters in Public Health from the Harvard School of Public Health. Dr. Kaye has authored over 300 peer-reviewed articles and 20 book chapters and has presented original research at national and international conferences. Dr. Kaye is Past President of the Society for Health Epidemiology of America (SHEA). He is a recognized expert in healthcare epidemiology and antimicrobial resistance and has been invited to speak on these topics at venues throughout the world. About Tebipenem HBr About Spero Therapeutics Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is designed to be the first oral carbapenem antibiotic for use in adults to treat serious bacterial infections, including those caused by MDR Gram-negative infections. In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in complicated urinary tract infection and acute pyelonephritis. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting. For more information, visit?https://sperotherapeutics.com. Forward-Looking Statements Spero Investor and Media Contact: |